Hyderabad, Feb. 27 -- Japanese firm Takeda and Biological E Limited (BE), a prominent India-based pharmaceutical company, have forged a strategic alliance aimed at providing access to QDENGA (Dengue Tetravalent Vaccine) to all. The collaboration intends to make these doses available for procurement by governments in endemic regions by 2030, facilitating National Immunization Programme.

Multi-dose vials offer economic and logistical advantages by reducing packaging and storage expenses, along with minimising medical and environmental waste.

According to the reports, the collaboration will escalate manufacturing capacity to produce up to 50 million doses annually, thereby supporting Takeda's goal to manufacture 100 million doses per year ...